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Background: Patients with iliofemoral deep venous thrombosis (DVT) are at highest risk for the postthrombotic
morbidity including all aspects of the postthrombotic syndrome. Invasive therapies such as catheter-directed thrombol-
ysis (CDT) and/or mechanical thrombectomy with or without angioplasty and stenting and in some cases open operative
thrombectomy improves venous patency, venous valve function, and quality of life in patients with acute iliofemoral
DVT. What is the current frequency of acute iliofemoral DVT and how aggressively is it being treated? We hypothesize
that the 10-year period frequency of iliofemoral DVT among acute DVT cases is greater than previously reported.
Further, we hypothesize that thrombus removal to treat acute iliofemoral DVT is little utilized in current practice.
Methods: Indiana University (IU) vascular laboratory records from January 1, 1998 to December 31, 2008 were searched
by CPT code for venous Doppler ultrasound study (n 7240). A random sample based on the IU medical record number
of lower extremity Doppler studies was then selected (n  1020) for retrospective chart review. Corresponding clinical
information was gathered from the patients’ electronic medical record.
Results: Acute DVT occurred in 6.8%, and chronic DVT in 8.8% of patients studied (25.7% inpatient, 61.7% female;
median age, 56.0 years [range, 4-91 years, 1.1% less than 16 years]). History of previous DVT (33.3%) and cancer (30.4%)
were the most common risk factors in patients with acute DVT. Iliofemoral DVT defined as having an iliac or common
femoral vein component was identified in 49.3% of acute DVT and in 36.0% of chronic DVT. CDT was utilized in 14.3%
and mechanical thrombectomy in 4.8% of acute iliofemoral DVT, and was never used with distal DVT. Warfarin
anticoagulation unfractionated heparin or low-molecular-weight heparin overlap was the most common treatment for
acute iliofemoral DVT (100.0%). In 2008, the referral base of our laboratory increased significantly. Acute DVT occurred
significantly less often during the 1-year period 2008 (5.3%) than the 10-year period 1998-2007 (7.6%), but iliofemoral
common femoral DVT as a component of acute DVT did not differ significantly.
Conclusions: Iliofemoral DVT may be more frequent than previously reported and represents a significant portion of acute
DVT. Current recommendations of acute thrombus removal for the treatment of iliofemoral DVT is underutilized
suggesting that perhaps greater education of clinicians and patients regarding invasive therapy for iliofemoral DVT is
required. (J Vasc Surg 2010;52:1272-7.)Iliofemoral deep venous thrombosis (DVT) carries signif-
icant physical, social, and economic consequences. Patients
with iliofemoral DVT are at highest risk for postthrombotic
morbidity including the postthrombotic syndrome (PTS).1-3
In addition, recent studies suggest that patients with high
proximal (iliac or proximal femoral vein) DVT have signifi-
cantly worse PTS severity than those with distal or popliteal
vein DVT.4-7
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1272Until recently, recommendations and standard of care
for this subset of venous occlusive disease was largely the
same as for DVT occurring more distally: systemic antico-
agulation alone. However, as surgical methodology has
advanced and catheterization technology has improved,
numerous studies have surfaced documenting that throm-
bus removal in addition to adequate anticoagulation im-
proves morbidity after iliofemoral DVT.8 The most recent
Chest guidelines reflect these conclusions.9 The guidelines
now recommend catheter-directed thrombolysis (CDT)
for extensive acute proximal (iliofemoral) DVT of less than
14 days since onset in patients with good functional status
and life expectancy greater than 1 year.10 Recommenda-
tions also include pharmacomechanical thrombolysis in
preference to CDT alone to shorten treatment,11-12 and
balloon angioplasty and stenting to correct underlying
venous lesions after CDT,13 followed by anticoagulation
therapy.
Despite an increasing focus on iliofemoral DVT, the
true rate of iliofemoral disease is not known and the defi-
nition not uniform. What then is the current frequency of
acute iliofemoral DVT and how aggressively is it being
treated? The primary purpose of this study is to perform a
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the Clarian/IU Vascular Diagnostic Laboratory. The goal
is to identify the frequency of iliofemoral DVT in the
screened population. The frequency of treatments pursued
(systemic thrombolysis, intravenous CDT, open thrombec-
tomy, pharmacomechanical thrombectomy, anticoagula-
tion alone) will also be identified.
METHODS
Patients. The Indiana University School of Medicine
serves the Clarian Hospital System (Methodist Hospital,
University Hospital, Riley Hospital for Children). One of
the Clarian system hospitals is a regional children’s hospital,
whereas the other two are tertiary-quaternary care facilities.
Corresponding clinical information was gathered from the
patients’ electronic medical record in Cerner PowerChart
and the office outpatient clinic chart. Such information
included patient history, presenting signs and symptoms,
laboratory results, treatment, and outcome if available.
None of the 18 HIPAA identifiers were acquired. The
protocol and conduct of this retrospective study were re-
viewed and approved by the Indiana University Institu-
tional Review Board.
Selection protocol. The IU School of Medicine Vas-
cular Surgery maintains a database (Vascubase; Consensus
Medical Systems, Inc, Seattle, Wash) of all Doppler studies
performed by our staff at the Clarian Hospital System.
Indiana University Vascular laboratory records from Janu-
ary 1, 1998 to December 31, 2008 were searched by CPT
code (93970, 93971, 93971RT, 93971LT) for venous
Doppler ultrasound studies (n 7240). No practice at the
IU/Clarian Hospital system routinely performs venous
Doppler studies in asymptomatic patients. TheDepartment
of Radiology also performed venous Doppler studies until
2008, but these records were not included in this study. No
specific referral pattern for venous studies between the IU
Vascular Lab and the Department of Radiology was en-
forced during this time period.
The Clarian Hospital System assigns all patients to a
medical record number based upon date of entrance (first
point of care) into the hospital system. The medical record
number is assigned to patients without bias toward age,
gender, or comorbidity. Studies were numerically ordered
by medical record number and one out of every seven
studies was consecutively chosen. Thus, a random sample
based on the IU medical record number of lower extremity
Doppler studies was then selected (n  1020) for retro-
spective chart review.
Ultrasound. In all patients, venous duplex ultra-
sonography was obtained. Our protocol includes routine
imaging from distal calf veins to the external iliac vein.
More proximal imaging (eg, common iliac) is obtained
depending on the presence of an abnormal respiratory or
distal augmentation waveform in the common femoral or
external iliac vein and/or the presence of DVT in these
same areas but is hindered in some cases by body habitus
and other patient variables. The criteria for acute DVT
included a new noncompressible vein segment, low levelechogenicity, acoustic homogeneity, smooth thrombus
surface characteristics, venous dilation, and an increase in
vein diameter of a known previous thrombus. The crite-
ria for chronic DVT included a small noncompressible
vein, high-level echogenicity, acoustic heterogeneity, ir-
regular thrombus surface characteristics, and presence of
collateral venous channels and recanalized segments.
Acute thrombosis on top of chronic changes was catego-
rized as acute DVT.
Study classification of lower extremity DVT location.
DVT was classified into categories according to the most
proximal vein segment involved. The location categories
were distal (calf vein), popliteal, femoral (superficial or
deep), common femoral, or iliac. Iliofemoral DVT was
defined as DVT involving iliac and/or common femoral
vein as the most proximal segment.
Treatment. Treatment categories included: aspirin,
81 mg or 325 mg daily alone; clopidogrel, 75 mg daily;
low-dose prophylactic unfractionated heparin or low-
molecular-weight heparin (usually enoxaparin); full-dose
intravenous unfractionated heparin, with a target-activated
partial thromboplastin time (aPTT) of 60 to 85 seconds or
two to three times the control aPTT value or enoxaparin 1
mg per kg twice-daily by subcutaneous injection; fondapa-
rinux (5-10 mg subcutaneous daily); warfarin with a target
international normalized ratio (INR) of 2.0 to 3.0; vena
caval filter; catheter-directed thrombolysis; and mechanical
thrombectomy either percutaneous or open.
Presentation of data and statistical analysis. All re-
ported values are mean  SEM. Data were analyzed using
frequency distribution. Data were compared using Student
t test. A probability value of less than .05 was considered
statistically significant.
RESULTS
Demographics. Females (61.7%) outnumbered males
(38.3%) in the entire study population. No significant
difference (P  .90) in gender was identified between the
random sample (female, 61.9%; male, 38.1%) and the
whole study population. Median age was 56.0 years [range,
4-97 years; 1.1% less than 16 years] (Fig 1, A). No signifi-
cant difference (P .23) in age was identified between the
random sample (56.4  0.5 years) and the whole study
population (55.7  0.3). The number of ultrasonographic
studies did fluctuate from 1 year to another (Fig 2, B).
Outpatient (74.3%) outnumbered inpatient (25.7%) stud-
ies. History of previous DVT (33.3%) and cancer (30.4%)
were the most common risk factors in patients with DVT.
Smoking (29.0%), recent surgery (27.5%), and hyperco-
agulability (5.8%) were also common risk factors in patients
with acute DVT. Of the hypercoagulable patients, 54.5%
demonstrated protein C deficiency and 18.2% hyperhomo-
cysteinemia.
Prevalence of DVT. AcuteDVT occurred in 6.8% and
chronic DVT in 8.8% of patients studied. Iliofemoral DVT
(iliac and/or common femoral vein) was identified in
49.3% of acute DVT and 36.0% of chronic DVT. No
isolated iliac vein acute thrombus was identified (Fig 2). In
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cantly, as the radiology department no longer provided
venous duplex ultrasonography. Acute DVT occurred sig-
nificantly less often during the 1-year period 2008 (5.3%)
than the 10-year period 1998-2007 (7.6%) and may reflect
practitioners who previously had used the radiology depart-
ment for low probability screening exams now used the
vascular lab. However, iliofemoral DVT as a component
of acute DVT did not differ significantly. No change in
system-wide DVT prophylaxis or treatment occurred dur-
ing the conduct of this study.
Treatment of DVT. CDT was utilized in 60% and
percutaneous mechanical thrombectomy in 20% of acute iliac
DVT and was never used with common femoral, femoral,
popliteal, or distal DVT (Fig 3). Overall, aggressive thrombus
removal was utilized in 2.4% of DVT patients. Percutaneous
mechanical thrombectomy was always used in conjunction
with thrombolysis. Warfarin anticoagulation  full-dose un-
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Fig 1. Demographic data. A, Age distribution of study popula-
tion. B, Year distribution of study population.fractionated heparin or low-molecular-weight heparin bridg-ing was the most common treatment for acute DVT (Fig 3).
Surprisingly, full anticoagulation was not used in all popliteal
DVT but was often used for distal DVT (Fig 3).
DISCUSSION
The results of this study demonstrate that in our large
population of patients referred to the vascular lab for ve-
nous duplex study that: (1) iliofemoral DVT may be more
prevalent than previously reported and represents a signif-
icant portion of acute DVT; and (2) current recommenda-
tions of acute thrombus removal for the treatment of
iliofemoral DVT and high proximal DVT is underutilized.
Definitions of lower extremity DVT location may be
confusing and are inadequate. Traditionally, lower extrem-
ity DVT is divided into distal (calf) or proximal (knee and
higher) DVT.14 Iliofemoral DVT is a subset of proximal
DVT, but the exact definition of iliofemoral DVT varies.
Some have defined that iliofemoral DVT must include a
component of iliac vein thrombus (iliac vein DVT alone,
iliac vein common femoral DVT, and iliac vein femoral
DVT).15 Common femoral DVT, which does not include
iliac vein thrombus, is often classified not as iliofemoral
DVT but as femoropopliteal DVT. In contrast, the Society
of Interventional Radiology defines acute iliofemoral DVT
as complete or partial thrombosis of any part of the iliac
vein and/or the common femoral vein with or without asso-
ciated femoropopliteal DVT, in which symptoms have been
present for 14 days or less or for which imaging studies
indicate that venous thrombosis has occurred within the
past 14 days.16 The common femoral vein segment is also
included with iliac vein in the Society of Interventional
Radiology (SIR) definition of iliofemoral DVT as both are
the final pathway out of the leg and are crucial for the
venous drainage of the lower limb. We concur with the
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Fig 2. Deep venous thrombosis (DVT) prevalence stratified by
location (most proximal extent of thrombus). Total, acute, and
chronic DVT as labeled and in this sequence for each location.definition of iliofemoral DVT as defined by the SIR and
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extent includes iliac vein or common femoral vein.
Few studies have addressed the prevalence of iliofemoral
DVT. An older study of 189 patients with symptomatic DVT
prior towidespread awareness ofDVTprophylaxis and duplex
ultrasonography utilized venography and determined that
43% of DVT involved the iliofemoral veins and 80% of DVT
involved the high proximal venous system (femoral, common
femoral, or iliofemoral veins).17 In a more recent study inves-
tigating only acute proximal (non-calf DVT), Douketis et al
found that iliac vein thrombosis occurred in only 4.4%of 1149
consecutive patients with symptomatic proximal DVT com-
pared with 39.4% with popliteal vein thrombosis and 56.1%
Fig 3. Acute deep venous thrombosis (DVT) treatment
Iliofemoral DVT. B, Femoropopliteal DVT. C, Distal D
ated heparin or low-molecular-weight heparin overlap bwith femoral vein thrombosis.1 In our study, which includedproximal and distal DVT, we determined that acute iliac vein
DVT comprised 8.7% of acute DVT and 4.5% of chronic
DVT. Common femoral DVT (40.6%) and femoral DVT
(27.5%) constituted the large majority of acute DVT in our
study, which paralleled the prevalence of femoral vein throm-
bosis (56.1%) in the study byDouketis et al1 Interestingly, our
study population that developed acute DVT also demon-
strated a high prevalence of prior DVT (33.3%); it remains
plausible that prior DVT might predispose one to increased
likelihood of developing iliofemoral DVT but this is un-
proven. Thus, iliac vein DVT may be more prevalent than
previously realized, but certainly common femoral DVT (a
subset of iliofemoral DVT) represents a significant burden of
fied by location (most proximal extent of thrombus). A,
n all cases of warfarin treatment, therapeutic unfraction-
g was also utilized.strati
VT. Iacute DVT.
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postthrombotic morbidity including the postthrombotic
syndrome (PTS).1-3 Interestingly, recent studies also sug-
gest that patients with extensive proximal (common femo-
ral, femoral, or iliac vein) DVT have significantly worse PTS
signs and symptoms than those with calf or popliteal vein
DVT.4-7 Stain et al determined that proximal DVT was the
strongest risk factor of PTS with an odds ratio (OR) of 2.1
in a study of 406 patients with acute DVT.5 Similarly, Kahn
et al found that in a study of 387 outpatients with acute
DVT, venous thrombosis of the common femoral or iliac
vein were predictors of higher PTS severity over time (OR,
2.23 vs distal DVT).6 The Multiple Environmental and
Genetic Assessment (MEGA) study, a large population-
based case control study of more than 2000 patients with
venous thromboembolism, also revealed that DVT in the
femoral and iliac vein was associated with a 1.3-fold in-
creased relative risk (RR, 1.3; 95% confidence interval [CI],
1.1-1.6) of PTS compared with popliteal vein thrombosis.7
Although many recent studies have focused on PTS after
iliofemoral DVT, proximal DVT is greater in prevalence
and may have a similar increased risk for PTS and reduced
quality of life.
Because PTS occurs in 40% of patients after DVT
despite adequate anticoagulation, numerous studies have
focused on early thrombus removal and demonstrated that
thrombolysis in addition to anticoagulation improves mor-
bidity after acute proximal DVT.8 Thus, the most recent
American College of Chest Physicians (ACCP) 2008
guidelines recommends CDT in patients with extensive
acute proximal DVT (eg, iliofemoral DVT), symptoms
14 days, and a low risk of bleeding.9 Interestingly, the
ACCP did not precisely define iliofemoral DVT nor did
they define extensive acute proximal DVT. Nevertheless,
despite rather impressive data in support for thrombus
removal in extensive proximal DVT aimed at decreasing the
PTS, clinicians are still reluctant to pursue thrombolytic
therapy. The perceived risk of bleeding, renal failure, and
even death with the use of thrombolytics in addition to the
efficacy of standard anticoagulation in preventing PE and
recurrent DVT remain barriers to early thrombolytic inter-
vention. Indeed, in our population, thrombolysis was used
in only 60% of iliac DVT and was never used in isolated
infrainguinal DVT (common femoral and more distal dis-
ease).
Based on the manner in which we categorized our
patients with DVT, the prevalence of calf vein thrombosis is
also noted. There is significant controversy on the proper
treatment of this disease state. The most recent ACCP
clinical guidelines have suggested early therapeutic antico-
agulation, which interestingly was applied in a significant
number of our patients. The disappointing observation was
that not all popliteal DVT were treated with therapeutic
anticoagulation. It is unclear if this was due to a misunder-
standing of the location of DVT or other factors.
Weaknesses of this study should be mentioned. Al-
though this is a retrospective study, the pertinent labora-
tory did have a standardization protocol for study perfor-mance that aids in minimizing variability according to
ICAVL standards. However, there is no ICAVL standard
for iliac vein evaluation that leaved this a less well-defined
area of study. In addition, ultrasound diagnosis of the iliac
vein segment may have poor sensitivity, as decreased fem-
oral phasicity may not occur with segmental iliac occlusion
when full imaging is not possible. Body habitus further
decreases ultrasonographic sensitivity of the iliac vein seg-
ments. Ultrasound findings were infrequently confirmed by
other methodologies. The study population represented a
subpopulation of our tertiary care population who were
referred to the vascular lab for venous study, which may
limit generalization to asymptomatic patients or other ter-
tiary facilities whose referral patterns do not include a
vascular ultrasound lab. Finally, the data analysis was lim-
ited by sampling design.
Further study is clearly needed to identify the preva-
lence and ideal treatment of iliofemoral DVT. In 2002,
Elsharawy et al reported on one of the first randomized
prospective trials of iliofemoral DVT patients treated with
CDT anticoagulation or anticoagulation alone that CDT
improved venous patency and decreased venous reflux.18
Similarly, early 6-month results from the Catheter-directed
Venous Thrombolysis in acute iliofemoral vein thrombosis
(CaVenT) study demonstrate increased iliofemoral patency
(36% vs 64%) and decreased venous obstruction (49.1% vs
20.0%) in the CDT arm.19 The Acute Venous Thrombosis:
Thrombus Removal with Adjunctive Catheter-Directed
Thrombolysis (ATTRACT) trial is an ongoing prospective
trial of iliofemoral versus femoropopliteal DVT patients
randomized to medical management with standard antico-
agulation versus catheter-directed thrombolysis with a pri-
mary outcome of postthrombotic syndromeover a 24-month
follow-up.20 We suspect that further prospective randomized
trials such as these may suggest greater efficacy of early clot
removal in iliofemoral DVT.
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